Wednesday 7th September 2022
Helping demystify multi-organ fibrosis: The DEMISTIFI study
Would you like to find out more about a new study that aims to improve how we understand and treat fibrosis?
Friday 15th July 2022
Six Months of STAR – the Symptom Tracking App for Raynaud’s
July marks six months since Scleroderma & Raynaud’s UK launched STAR, the Symptom Tracking App for Raynaud’s, which enables members of the SRUK community to track their Raynaud's attacks and directly contribute to essential scientific research into the condition. Here’s a breakdown of what we’ve learnt so far, thanks to the STAR community!
Tuesday 28th June 2022
‘Olive Ayoub Intermediate to Late-Stage Post-Doctoral Research Fellowship’ Opens for Applications on 29th June
On 29th June, Scleroderma & Raynaud’s UK will open applications for the Olive Ayoub Intermediate to Late-Stage Post-doctoral Research Fellowship, which will enable one exceptional, non-tenured post-doctoral researcher to transition from postdoc to research leader in the field of scleroderma.
Friday 24th June 2022
Identifying Scleroderma Patients at Risk of Pulmonary Hypertension - US Study Provides Potential Biomarker for the Condition
A new US study has found that scleroderma patients who test positive for ‘anti-Th/To antibodies’ are at higher risk of developing pulmonary hypertension (PH) in comparison to other patients, which could enable the earlier detection and more effective management of one of scleroderma’s most serious complications.
Wednesday 8th June 2022
Innovative Medicines Fund: Accelerating treatments to the rare disease community
Yesterday saw the launch of the Innovative Medicines Fund (IMF) - a scheme which will give NHS patients living in England, including those with rare diseases like Scleroderma, the chance to have ‘early’ access to cutting-edge treatments offering them the best chances of a longer and healthier life.
Thursday 26th May 2022
Getting a Grip on Scleroderma: Double Hand Transplant for Scleroderma Patient
A British man has become the first Scleroderma patient to receive a double hand transplant for the condition, giving him a new lease of life and prompting hope for many of those most severely affected by the condition.
Tuesday 10th May 2022
The VEDOSS Project – Predicting the Progression of Raynaud’s to Systemic Sclerosis
New research suggests the ‘VEDOSS’ Criteria could be used to accurately predict which individuals living with Raynaud's are likely to progress to Systemic Sclerosis, prompting further hope regarding the early detection and treatment of the condition.
Friday 22nd April 2022
Developing the Next Generation of Medicine
SRUK co-funds a MRC Clinical Research Training Fellowship to advance research into treatments for interstitial lung disease.
Wednesday 20th April 2022
Grant Call: Quality of Life
Ongoing research towards developing new treatments and therapies has a cumulative effect in improving quality of life, but can the problem be addressed directly?
Friday 25th March 2022
New treatment which prevents COVID-19 infection in immunocompromised adults approved in UK
On the 17th March 2022 the UK’s Medicine and Health products Regulation Agency (MHRA) approved a new drug, Evusheld, for the prevention of COVID-19 infection.